Drug Profile
BHQ 880
Alternative Names: Anti-DKK1 mAb; Anti-DKKK-1 neutralising antibody (BHQ880); BHQ-880Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator MorphoSys; Novartis
- Class Antibodies; Antineoplastics; Monoclonal antibodies
- Mechanism of Action DKK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple myeloma; Smoldering multiple myeloma
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
- 20 Aug 2015 BHQ 880 is still in phase-II development for Multiple myeloma in USA and Europe
- 01 Nov 2013 Novartis completes a phase II trial in Smoldering Multiple myeloma (treatment naive, monotherapy) in USA, Germany and France (IV) (NCT01302886)